PharmTech Weekly News Roundup – Week of January 26, 2026

In this PharmTech video feature, we highlight the week’s industry news in an easy-to-consume, fun format. New roundups will drop every Friday, so be sure to come back each week.

Collectively, the week’s coverage discusses the pharmaceutical industry’s recent developments and current regulatory landscape. Read on for recaps of each story we’ve covered.

Mirum Acquires Bluejay, Adding Brelovitug Treatment for HDV

Mirum Pharmaceuticals acquired Bluejay Therapeutics to develop brelovitug, a late-stage monoclonal antibody treatment for chronic hepatitis delta virus patients.

US Withdrawal From WHO Creates New Pharma Logistics Vulnerabilities

The United States’ withdrawal from the WHO threatens global regulatory alignment, supply chain stability, and international pharmaceutical research collaborations.

WuXi Biologics Collabs with HanchorBio on Next-Generation Fusion Protein Pipelines

WuXi Biologics and HanchorBio partnered to accelerate multi-functional fusion protein development using end-to-end CMC and GMP manufacturing services.

Halo Pharma Becomes Dedicated North American Drug Product CDMO

Halo Pharma transitioned into a standalone North American drug product CDMO, specializing in complex formulations and expanding sterile manufacturing capacity.

Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases

Repertoire Immune Medicines and Eli Lilly are collaborating to develop autoimmune disease therapies using the DECODE T-cell receptor discovery platform.

Cellares Secures $257M to Scale Global Cell Therapy Manufacturing

Cellares raised $257 million to industrialize cell therapy manufacturing using automated smart factories and an integrated development manufacturing organization model.

ROSS Announces CDA-200 Dual Shaft Mixer for Processing Viscous Pharmaceuticals

ROSS launched the CDA-200 Dual Shaft Mixer to provide high-speed dispersion and agitation for processing complex, high-viscosity pharmaceutical formulations.

Vetter Announces Plan to Build Manufacturing Site in Germany with €1.5 Billion CDMO Investment

Vetter is investing €1.5 billion to expand global sterile injectable manufacturing capacity through new facilities in Germany and Illinois.

Lilly Invests $3.5B in Pennsylvania Injectable Medicine Facility

Eli Lilly is investing $3.5 billion in a Pennsylvania facility to manufacture next-generation injectable weight-loss therapies using advanced technology.

Securing Radiopharma and GLP-1 Supply Chains Through 2026 M&A

Bain’s 2026 report analyzes how pharmaceutical firms utilize M&A for vertical integration and manufacturing control to secure fragile supply.